After a 25% crash, is this ASX 200 stock in deep value territory?

This $13 billion company has been kicked the curb. It might be worth inspecting.

| More on:
a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Not all stocks featured in the S&P/ASX 200 Index (ASX: XJO) have performed as swimmingly as the benchmark. Some of the index's biggest constituents meet the 'crash' criteria — falling 20% or more — despite the ASX 200 being up 10.3% over the past 12 months.

Sometimes, this visible divergence between the broader market and individual companies is where 'deep value' can be discovered. If the pessimism is misplaced, these shares can suddenly spring back once investors realise it.

I think a 90-year-old cornerstone of the healthcare industry has fallen into this camp.

No more pandemic hangover for this ASX 200 stock

The COVID-19 pandemic injected a huge boost to Sonic Healthcare Ltd (ASX: SHL) between 2020 and 2022. As a pathology and laboratory heavyweight, Sonic's revenues surged from all the COVID-19 testing needed during this time.

In FY2022, approximately 26% of Sonic Healthcare's record-breaking $9.3 billion revenue came from COVID testing. However, demand for such services has rapidly dwindled since, falling to only $39 million in the first half of FY2024.

Where's the good news in losing roughly $2.4 billion of revenue in two years?

Well, the impact from here is capped at $39 million. Because of this, we can begin focusing back on the company's base business: traditional pathology, laboratory, and radiology services. Without the anchor of falling COVID revenues, we may start seeing a recovery in earnings.

Survival of the biggest

This ASX 200 stock currently trades at a price-to-earnings (P/E) ratio of 25 times. For reference, the global healthcare industry average is around 23 times earnings. Based on this, Sonic Healthcare appears to be nowhere near 'deep value' relative to its peers.

However, it's worth thinking about the industry dynamics currently at play.

Rising costs and flat medical rebates are putting pressure on the entire diagnostics industry. I believe this will create an environment where only the largest operators can succeed. Personally, I think this is why we're seeing Sonic Healthcare gobble up smaller competitors abroad.

There is some intrinsic value in being one of the biggest players.

Given the industry headwinds, I don't know if this ASX 200 stock can be labelled 'deep value'. However, the current $26.68 price tag is attractive when I take a long-term perspective on the company.

Motley Fool contributor Mitchell Lawler has positions in Sonic Healthcare. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Sonic Healthcare. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Opinions

A businessman hugs his computer and smiles.
Opinions

If I could only own one ASX 200 share for the rest of my life, it'd be this one

This is one stock I expect to own forever.

Read more »

Man ponders a receipt as he looks at his laptop.
Technology Shares

Brokers rerate 3 leading ASX 200 tech stocks

Experts reveal their ratings on the ASX 200 tech sector's three biggest companies.

Read more »

Person holding a blue chip.
Opinions

Buy alert! 2 ASX 200 blue-chip shares worth a look now: expert

Dylan Evans from Catapult Wealth has identified two blue-chip shares that he thinks are good buys today.

Read more »

Two happy woman on a couch looking at a tablet.
Opinions

Why I'm excited to see the results of these ASX 200 shares

These stocks could reveal very interesting insights.

Read more »

Young male investor smiling looking at laptop as the share price of ASX ETF CRYP goes higher today
Opinions

Why I just bought this 5.2%-yielding ASX dividend stock and plan to buy even more

This business is one of my favourites for dividends and total returns.

Read more »

A young female investor with brown curly hair and wearing a yellow top and glasses sits at her desk using her calculator to work out how much her ASX dividend shares will pay this year
Opinions

Why I'm still investing in ASX shares during tariff uncertainty

There are a few reasons why I plan to continue investing even during uncertainty.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Opinions

Why I'm buying more of these 2 ASX stocks ahead of earnings season

I've been excited about buying these investments.

Read more »

Business women working from home with stock market chart showing per cent change on her laptop screen.
Opinions

1 month until ASX earnings season begins: how I'm preparing

It’s almost reporting time. Here’s what I’m looking at.

Read more »